Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation?

Nikolaos Spinthakis, Mohamed Farag, Zaki Akhtar, Diana Adrienne Gorog

Research output: Contribution to journalReview articlepeer-review

18 Downloads (Pure)

Abstract

BACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.

METHODS: Here we review studies using more potent antithrombotic agent combinations to reduce this risk, namely triple therapy (TT) with the addition of an oral anticoagulant, PAR-1 antagonist, or cilostazol to DAPT (mainly aspirin and clopidogrel), and discuss the limitations of trials to date.

RESULTS: Generally speaking, TT leads to an increase in bleeding. Vorapaxar showed a signal for reducing ischaemic events, but increased intracranial haemorrhage 3-fold in the subacute phase of ACS, although remains an option for secondary prevention beyond the immediate subacute phase, particularly if prasugrel or ticagrelor are not available. Non-vitamin K oral anticoagulants (NOACs) all increased bleeding, with only modest reduction in MACE noted with low dose rivaroxaban. Rivaroxaban can be considered combined with aspirin and clopidogrel in ACS patients at high ischaemic and low bleeding risk, without prior stroke/TIA. The combination of P2Y12 inhibitor and NOAC, without aspirin, looks promising. DAPT may be replaced, not by TT, but by dual therapy comprising a NOAC with a P2Y12 inhibitor.

CONCLUSION: More potent antithrombotic regimens increase bleeding and should only be considered on an individual basis, after careful risk stratification. Accurate risk stratification of ACS patients, for both ischaemic and bleeding risk, is essential to allow individualised treatment.

Original languageEnglish
Pages (from-to)427-436
Number of pages10
JournalCurrent vascular pharmacology
Volume16
Issue number5
Early online date16 Jan 2018
DOIs
Publication statusPublished - 2018

Keywords

  • Acute coronary syndromes
  • Apixaban
  • Dabigatran
  • Edoxaban
  • Newer oral anticoagulants
  • Rivaroxaban
  • Thrombosis

Fingerprint

Dive into the research topics of 'Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation?'. Together they form a unique fingerprint.

Cite this